Rosen T.Update on treating uncomplicated skin and skin structure infections. J DrugsDermatol.2004;4(6 suppl): S9-S14.
2.
Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41:1373-1406.
3.
Mangram AJA brief overview of the 1999 CDC Guideline for the Prevention of Surgical Site Infection. Centers for Disease Control and Prevention. J Chemother. 2001;13:35-39.
4.
Mancini AJBacterial skin infections in children: the common and the not so common . Pediatr Ann. 2000;29:26-35.
5.
Oumeish I., Oumeish OY, Bataineh O.Acute bacterial skin infections in children. Clin Dermatol . 2000;18:667-678.
6.
Hedrick J.Acute bacterial skin infections in pediatric medicine: current issues in presentation and treatment. Paediatr Drugs. 2003;5(suppl 1):35-46.
7.
Larsen F., Hanifin JMEpidemiology of atopic dermatitis. Immunol Allergy Clin North Am. 2002;22:1-24.
8.
Leung DYAtopic dermatitis: new insights and opportunities for therapeutic intervention . J Allergy Clin Immunol. 2000 ;105:860-876.
9.
Baker BSThe role of microorganisms in atopic dermatitis. Clin Exp Immunol. 2006;144:1-9.
Sladden MJ, Johnston GAMore common skin infections in children. BMJ. 2005;330:1194-1198.
12.
O'Dell MLSkin and wound infections: an overview. Am Fam Physician. 1998;57:2424-2432.
13.
Hijazy M.Principles of Pediatric Dermatology. http://www.dermatologyinfo.net/english/ebook.htm . Accessed October 6, 2006.
14.
Ladhani S., Garbash M.Staphylococcal skin infections in children: rational drug therapy recommendations . Paediatr Drugs. 2005;7:77-102.
15.
Perera G., Hay R.A guide to antibiotic resistance in bacterial skin infections. J Eur Acad Dermatol Venereol. 2005;19:531-545.
16.
Roth RR, James WDMicrobiology of the skin: resident flora, ecology, infection. J Am Acad Dermatol. 1989;20: 367-390.
17.
Marples MJThe normal flora of the human skin. Br J Dermatol.1969;81(suppl 1):2-13.
18.
Steinberg JP , Clark CC, Hackman BONosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance. Clin Infect Dis.1996 ;23:255-259.
19.
Lowy FDStaphylococcus aureus infections. N Engl J Med. 1998;339:520-532.
20.
Mainous AG III, Hueston WJ, Everett CJ, et al. Nasal carriage of Staphylococcus aureus and methicillin-resistant S. aureus in the United States, 2001-2002. Ann Fam Med.2006 ;4:132-137.
21.
Ladhani S., Joannou CL, Lochrie DP, et al. Clinical, microbial, and biochemical aspects of the exfoliative toxins causing staphylococcal scalded-skin syndrome. Clin Microbiol Rev. 1999;12:224-242.
22.
Lubbe J.Secondary infections in patients with atopic dermatitis. Am J Clin Dermatol. 2003;4:641-654.
23.
Ong PY, Ohtake T., Brandt C., et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002;347:1151-1160.
24.
Diep BA, Gill SR, Chang RF, et al. Complete genome sequence of USA300, an epidemic clone of community-acquired methicillin-resistant Staphylococcus aureus. Lancet. 2006;367:731-739.
25.
Cohen PRCutaneous community-acquired methicillin-resistant Staphylococcus aureus infection: a personal perspective of a worldwide epidemic. Expert Rev Dermatol. 2006;1:631-637.
26.
Chen AE, Goldstein M., Carroll K., et al. Evolving epidemiology of pediatric Staphylococcus aureus cutaneous infections in a Baltimore hospital. Pediatr Emerg Care. 2006;22:717-723.
Darmstadt GL , Lane ATImpetigo: an overview. Pediatr Dermatol. 1994;11:293-303.
29.
Eron LJ, Lipsky BA, Low DE, et al. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother. 2003;52(suppl 1): 13-17.
30.
Scher RK, Elston DM, Hedrick JA, et al. Treatment options in the management of uncomplicated skin and skin structure infections. Cutis.2005;75(suppl 1):3-23.
31.
Darmstadt GLAntibiotics in the management of pediatric skin disease. Dermatol Clin. 1998;16:509-525.
32.
Lin RYA perspective on penicillin allergy. Arch Intern Med . 1992;152:930-937.
33.
Pichichero MEA review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients. Pediatrics. 2005;115:1048-1057.
34.
Pichichero MECephalosporins can be prescribed safely for penicillin-allergic patients. J Fam Pract. 2006;55: 106-112.
35.
Gilbert DNAspects of the safety profile of oral antibacterial agents. Infect Dis Clin Pract.1995;4(suppl 2): S103.
36.
Randolph MF , Morris KEClindamycin-associated colitis in children. A prospective study and a negative report. Clin Pediatr (Phila). 1977;16:722-725.
37.
Elston DMOptimal antibacterial treatment of uncomplicated skin and skin structure infections: applying a novel treatment algorithm. J DrugsDermatol.2005;4(suppl 6): S15-S19.
38.
Marcinak JF , Frank ALTreatment of community-acquired methicillin-resistant Staphylococcus aureus in children. Curr Opin Infect Dis. 2003;16:265-269.
39.
Thornton Spann C., Taylor SC, Weinberg JMTopical antimicrobial agents in dermatology . Clin Dermatol.2003 ;21:70-77.
40.
Thornton Spann C., Tutrone WD, Weinberg JM, et al. Topical antibacterial agents for wound care: a primer. Dermatol Surg.2003;29:620-626.
41.
Deshpande LM , Pfaller MA, Fix AM, et al. Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods. Diagn Microbiol Infect Dis.2002;42:283-290.
42.
Gales AC, Andrade SS, Sader HS, et al. Activity of mupirocin and 14 additional antibiotics against staphylococci isolated from Latin American hospitals: report from the SENTRY antimicrobial surveillance program. J Chemother. 2004;16:323-328.
43.
Kaye ETTopical antibacterial agents. Infect Dis Clin North Am. 2000;14:321-339.
44.
Akins RL, Haase KKGram-positive resistance: pathogens, implications, and treatment options: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2005;25:1001-1010.
45.
Lewis JS II, Jorgensen JHInducible clindamycin resistance in Staphylococci: should clinicians and microbiologists be concerned?Clin Infect Dis.2005;40:280-285.
46.
Schweiger ES , Weinberg JMNovel antibacterial agents for skin and skin structure infections. J Am Acad Dermatol. 2004;50:331-340.
47.
Kardas P., Devine S., Golembesky A., et al. A systematic review and meta-analysis of misuse of antibiotic therapies in the community. Int J Antimicrob Agents. 2005;26: 106-113.
48.
Kardas P.Patient compliance with antibiotic treatment for respiratory tract infections . J Antimicrob Chemother. 2002;49:897-903.
49.
Rist T., Parish LC, Capin LR, et al. A comparison of the efficacy and safety of mupirocin cream and cephalexin in the treatment of secondarily infected eczema. Clin Exp Dermatol. 2002;27:14-20.
50.
Gardiner P. , Dvorkin L.Promoting medication adherence in children . Am Fam Physician. 2006;74:793-798.
51.
Steele RW, Thomas MP, Begue RECompliance issues related to the selection of antibiotic suspensions for children . Pediatr Infect Dis J. 2001;20:1-5.
52.
Mupirocin [prescribing information]. http://us.gsk.com/ . Accessed October 6, 2006.
53.
Gales AC, Sader HS, Andrade SS, et al. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int J Antimicrob Agents. 2006;27:300-302.
Free A., Roth E., Dalessandro M., et al. Retapamulin ointment twice daily for 5 days vs oral cephalexin twice daily for 10 days for empiric treatment of secondarily infected traumatic lesions of the skin. SkinMed. 2006; 5:224-232.
56.
Parish LC, Jorizzo JL, Breton JJ, et al. Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: results of a randomized controlled trial. J Am Acad Dermatol. 2006;55:1006-1016.
